EUCTR2007-000394-36-BG进行中（未招募）不适用
A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND DOCETAXEL AS A COMBINATION CHEMOTHERAPY REGIMEN FOR BREAST CANCER
Hospira UK Ltd0 个研究点目标入组 279 人开始时间: 2008年3月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 279
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Females = 18 and = 70 years of age;
- •2. Written informed consent given;
- •3. Subjects with invasive breast cancer appropriate for treatment with doxorubicin and docetaxel combination therapy in the neo-adjuvant, adjuvant or first line metastatic treatment setting, who have not previously received treatment with anthracyclines or taxanes;
- •4. Any acute adverse effects of prior therapy must have resolved to = NCI CTCAE (Version 3.0) grade 1 (excluding alopecia) prior to Day 1 of Cycle 1;
- •5. ECOG Performance Status 0 or 1 as determined on Day 1 of Cycle 1 prior to administration of chemotherapy;
- •6. Adequate bone marrow function, as determined within 1 day prior to administration of chemotherapy on Day 1 of Cycle 1 and as indicated by:
- •Hb = 10 g/dL (transfusion permitted)
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Platelets = 100 x 109/L
- •7. Adequate renal and hepatic function, as determined within 1 day prior to administration of chemotherapy on Day 1 of Cycle 1 and as indicated by:
- •Creatinine <1.5 x ULN
- •Total bilirubin within normal reference range (unless elevation is known to be due to Gilbert’s disease)
- •Subjects must also meet one of the following criteria:
- •a. Alkaline phosphatase within normal reference range and both AST and ALT <2.5 x ULN; or
- •b. Alkaline phosphatase <2.5 x ULN and both AST and ALT <1.5 x ULN; or
- •c. Alkaline phosphatase <5 x ULN and both AST and ALT within normal reference range
- •8. Female subjects with reproductive potential must have a negative urine pregnancy test within 3 days prior to the first dose of chemotherapy (Day 1 of Cycle 1) and must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include IUD, oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository);
- •9. Estimated life-expectancy >6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Chemotherapy within the 4 weeks prior to the first dose of chemotherapy (Day 1 of Cycle 1) (or a longer period depending on the defined characteristics of the agents used
- •e.g., 6 weeks for mitomycin);
- •2. Radiotherapy within the 6 weeks prior to the first dose of chemotherapy, except for localised spot radiotherapy for bone metastases (Day 1 of Cycle 1);
- •3. Any prior radiotherapy to the mediastinal/pericardial region;
- •4. Any concurrent anti-cancer therapy, including endocrine therapy (with the exception of corticosteroids),
- •immunotherapy and monoclonal antibody therapy. Concurrent treatment with bisphosphonates is also excluded unless the subject has been on a stable dose for four weeks prior to the first dose of chemotherapy (Day 1 of Cycle 1);
- •5. Receipt of a non-registered, investigational agent as part of a clinical trial within 3 months prior to the first dose of chemotherapy (Day 1 of Cycle 1);
- •6. Receipt of a registered agent as part of a clinical trial if final study follow-up visit is within 30 days of start of chemotherapy (Day 1 of Cycle 1);
- •7. Prior bone marrow or stem cell transplant;
- •8. Any known myeloid abnormality (to include a pre-malignant myeloid condition or malignant condition);
- •9. Subjects who, in the Investigator’s opinion, have had extensive prior radiotherapy to a significant area of the bone marrow potentially affecting myelopoiesis;
- •10. Co-existing active infection, or received systemic anti-infectives for the treatment of infection within 72 hours prior to the first dose of chemotherapy (Day 1 of Cycle 1);
- •11. Significant cardiovascular disease as defined by:
- •a. History of congestive heart failure requiring therapy;
- •b. History of unstable angina pectoris or myocardial infarction within 6 months prior to screening;
- •c. Presence of severe valvular heart disease;
- •d. Presence of an arrhythmia requiring treatment.
- •12. Any co-existing medical condition that in the Investigator’s judgement will substantially increase the risk associated with the subject’s participation in the study.
- •13. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures;
- •14. Clinically symptomatic brain metastases (baseline computerized tomography (CT) or magnetic resonance imaging (MRI) scan of the brain required only if there is clinical suspicion of central nervous system metastases);
- •15. Known hypersensitivity to E. coli-derived products or other drugs formulated with polysorbate 80;
- •16. Previously received any G-CSF;
- •17. Uncontrolled hypercalcaemia (>NCI CTCAE (Version 3.0) grade 1);
- •18. Second malignancy (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix);
- •19. Pregnant or breast-feeding women;
- •20. Concomitant treatment with lithium or lithium products;
- •21. Hereditary fructose intolerance;
- •22. Concurrent treatment with erythropoietin or prior treatment within 4 weeks prior to the first dose of chemotherapy (Day 1of Cycle 1).
研究者
相似试验
已完成
不适用
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NON-INFERIORITY STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR PLUS LAMIVUDINE COMPARED TO DOLUTEGRAVIR PLUS TENOFOVIR/EMTRICITABINE IN HIV-1-INFECTED TREATMENT-NAÏVE ADULTS-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-030-16ViiV Healthcare UK Limited,22
未知
不适用
A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEFTAROLINE FOSAMIL (600 MG EVERY 8 HOURS) VERSUS VANCOMYCIN PLUS AZTREONAM IN THE TREATMENT OF PATIENTS WITH COMPLICATED BACTERIAL SKIN AND SOFT TISSUE INFECTIONS WITH EVIDENCE OF SYSTEMIC INFLAMMATORY RESPONSE OR UNDERLYING COMORBIDITIESPER-029-12AstraZeneca AB,35
进行中（未招募）
1 期
A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosisrinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosisMedDRA version: 18.1Level: PTClassification code 10046543Term: Urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000507-44-ESIpsen Innovation408
招募中
不适用
A STUDY TO INVESTIGATE DYSPORT® FOR THE TREATMENT OF SUBJECTS WITH LOSS OF BLADDER CONTROL AND INVOLUNTARY URINATION AS A RESULT OF SPINAL CORD INJURY OR MULTIPLE SCLEROSIS-N039 Chronic nephritic syndrome, unspecifiedChronic nephritic syndrome, unspecifiedN039PER-041-16Ipsen Innovation,17
进行中（未招募）
1 期
A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosisrinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosisMedDRA version: 18.1Level: PTClassification code 10046543Term: Urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000507-44-FRIpsen Innovation408